We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
-15.35%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$95.5M
AUM Growth
-$40.1M
(-30%)
Cap. Flow
+$254M
Cap. Flow
% of AUM
266.32%
Top 10 Holdings %
Top 10 Hldgs %
44.8%
Holding
389
New
183
Increased
50
Reduced
47
Closed
99
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$10.6M |
| 2 |
Baxter International
BAX
|
+$3.81M |
| 3 |
Akebia Therapeutics
AKBA
|
+$2.87M |
| 4 |
OTIC
Otonomy, Inc.
OTIC
|
+$2.46M |
| 5 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$1.81M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$8.82M |
| 2 |
CELG
Celgene Corp
CELG
|
+$6.57M |
| 3 |
DYAX
DYAX CORPORATION
DYAX
|
+$6.35M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$5.44M |
| 5 |
Viatris
VTRS
|
+$2.57M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 48.43% |
| 2 | Technology | 4.06% |
| 3 | Consumer Discretionary | 2.5% |
| 4 | Consumer Staples | 1.74% |
| 5 | Materials | 1.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AERI
101
DELISTED
Aerie Pharmaceuticals
AERI
| $153K | 0.16% |
+12,614
| New | +$200K |
|
|
CLVS
102
DELISTED
Clovis Oncology, Inc.
CLVS
| $150K | 0.16% |
7,810
-1,850
| -19% | -$39.2K |
|
103
CALL
Bausch Health
BHC
$1.8B
| $148K | 0.16% |
137,000
+18,500
| +16% | +$1.37M |
|
104
PTC Therapeutics
PTCT
$6.52B
| $148K | 0.16% |
22,954
+21,379
| +1,357% | +$371K |
|
|
105
CALL
Chipotle Mexican Grill
CMG
$44.2B
| $147K | 0.15% |
385,000
-290,000
| -43% | -$2.76M |
|
106
CALL
Colgate-Palmolive
CL
$74.4B
| $146K | 0.15% |
+126,800
| New | +$8.44M |
|
107
CALL
Alnylam Pharmaceuticals
ALNY
$35.7B
| $144K | 0.15% |
+40,000
| New | +$2.66M |
|
108
CALL
Boeing
BA
$169B
| $144K | 0.15% |
+45,000
| New | +$5.58M |
|
109
CALL
Electronic Arts
EA
$52.4B
| $140K | 0.15% |
61,000
+21,000
| +53% | +$1.34M |
|
110
PUT
Apple
AAPL
$4.9T
| $139K | 0.15% |
+232,000
| New | +$5.78M |
|
111
PUT
AT&T
T
$152B
| $137K | 0.14% |
171,458
+86,987
| +103% | +$2.41M |
|
112
CALL
PepsiCo
PEP
$187B
| $136K | 0.14% |
223,100
+128,000
| +135% | +$12.6M |
|
113
Alphabet (Google) Class C
GOOG
$4.22T
| $134K | 0.14% |
+3,600
| New | +$129K |
|
|
ALR
114
PUT
DELISTED
Alere Inc
ALR
| $124K | 0.13% |
+50,200
| New | +$2.41M |
|
115
Tonix Pharmaceuticals
TNXP
$198M
| – | – |
0
| – | – |
|
|
ESPR
116
CALL
DELISTED
Esperion Therapeutics
ESPR
| $117K | 0.12% |
92,200
+82,200
| +822% | +$1.32M |
|
|
BLUE
117
PUT
DELISTED
bluebird bio
BLUE
| $110K | 0.12% |
826
-2,285
| -73% | -$1.4M |
|
118
CALL
Infosys
INFY
$46.5B
| $110K | 0.12% |
+152,600
| New | +$1.33M |
|
|
K
119
CALL
DELISTED
Kellanova
K
| $109K | 0.11% |
+148,035
| New | +$10.2M |
|
120
CALL
lululemon athletica
LULU
$13.2B
| $107K | 0.11% |
+20,000
| New | +$1.2M |
|
121
Lumen
LUMN
$6.47B
| $105K | 0.11% |
+3,300
| New | +$92.5K |
|
122
CALL
Public Storage
PSA
$55.8B
| $103K | 0.11% |
+20,000
| New | +$5.05M |
|
|
123
CALL
Alphabet (Google) Class C
GOOG
$4.22T
| $102K | 0.11% |
+60,000
| New | +$2.15M |
|
|
WWAV
124
CALL
DELISTED
The WhiteWave Foods Company
WWAV
| $99K | 0.1% |
+100,500
| New | +$3.82M |
|
|
CLVS
125
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
| $98K | 0.1% |
29,600
-10,100
| -25% | -$214K |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q1 2016 Portfolio in Review
As of Q1 2016, FT Options held 389 positions worth $95.5M, down 30% from $136M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
FT Options deployed $254M of net new capital in Q1 2016, opening 183 new positions and adding to 50 existing holdings. Its largest new stake was Baxter International: 100,000 shares worth $4.11M.
By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 43% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Gilead Sciences, an estimated $8.82M trimmed.
- FT Options's largest Q1 2016 buy was Baxter International: 100,000 shares worth $4.11M.
- FT Options added most to Regeneron Pharmaceuticals in Q1 2016, an estimated $10.6M increase.
- FT Options's biggest Q1 2016 reduction was Gilead Sciences, cutting an estimated $8.82M.
- FT Options fully exited Celgene Corp in Q1 2016, selling an estimated $6.57M.
- FT Options's ten largest holdings make up 45% of its $95.5M portfolio in Q1 2016.
- FT Options opened 183 new positions and closed 99 in Q1 2016.
- FT Options's portfolio value fell 30% quarter-over-quarter to $95.5M.
Based on FT Options's 13F filing for Q1 2016, filed 9 May 2016.